Singapore, Feb. 19 -- Australia based diagnostic company, Minomic International Ltd has announced that the company has executed an agreement with US based pathology laboratory, Cirrus Dx.

The agreement allows Cirrus Dx to perform MiCheck(R) as a Laboratory Developed Test (LDT) in the company's Rockville MD based laboratory once internal validation is completed. Finalising this agreement completes an important step in commercialising MiCheck(R) in the healthcare market.

Dr Brad Walsh, Minomic's CEO said, "Being able to offer MiCheck(R) as an LDT through our partnership with Cirrus Dx will provide the Company with three important outcomes, 'Real World Data' which can be used in subsequent FDA approval submissions, validation of MiCheck(R)...